Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate

@article{Abrahamsen2013NationwideRA,
  title={Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate},
  author={Bo Abrahamsen and Erik Lerkevang Grove and Peter Vestergaard},
  journal={Osteoporosis International},
  year={2013},
  volume={25},
  pages={757-762}
}
National registers showed that a large proportion of patients treated with strontium ranelate have conditions that may now contraindicate use. The risk of death in strontium ranelate-treated patients was significantly higher than that seen in users of other osteoporosis drugs even after adjusting for cardiovascular risk factor profile. The European Medicines Agency (EMA) recently warned that strontium ranelate should be avoided in patients with ischaemic heart disease (IHD), peripheral vascular… CONTINUE READING